These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20029816)

  • 1. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.
    Burda ST; Viswanath R; Zhao J; Kinge T; Anyangwe C; Tinyami ET; Haldar B; Powell RL; Jarido V; Hewlett IK; Nyambi PN
    J Med Virol; 2010 Feb; 82(2):187-96. PubMed ID: 20029816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
    Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
    J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.
    Santoro MM; Ciccozzi M; Alteri C; Montieri S; Alexiev I; Dimova I; Ceccherini-Silberstein F; Beshkov D; Rezza G; Perno CF
    AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1133-8. PubMed ID: 18788909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia.
    Ong LY; Razak SN; Lee YM; Sri La Sri Ponnampalavanar S; Syed Omar SF; Azwa RI; Tee KK; Kamarulzaman A
    J Med Virol; 2014 Jan; 86(1):38-44. PubMed ID: 24127302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.
    Kebe K; Thiam M; Diagne Gueye NR; Diop H; Dia A; Signate Sy H; Charpentier C; Belec L; Mboup S; Toure Kane C
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):242-9. PubMed ID: 22860571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
    Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
    Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.
    Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L
    J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.
    Bokharaei-Salim F; Esghaei M; Khanaliha K; Kalantari S; Marjani A; Fakhim A; Keyvani H
    PLoS One; 2020; 15(3):e0229275. PubMed ID: 32119691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
    Rhee SY; Blanco JL; Jordan MR; Taylor J; Lemey P; Varghese V; Hamers RL; Bertagnolio S; Rinke de Wit TF; Aghokeng AF; Albert J; Avi R; Avila-Rios S; Bessong PO; Brooks JI; Boucher CA; Brumme ZL; Busch MP; Bussmann H; Chaix ML; Chin BS; D'Aquin TT; De Gascun CF; Derache A; Descamps D; Deshpande AK; Djoko CF; Eshleman SH; Fleury H; Frange P; Fujisaki S; Harrigan PR; Hattori J; Holguin A; Hunt GM; Ichimura H; Kaleebu P; Katzenstein D; Kiertiburanakul S; Kim JH; Kim SS; Li Y; Lutsar I; Morris L; Ndembi N; Ng KP; Paranjape RS; Peeters M; Poljak M; Price MA; Ragonnet-Cronin ML; Reyes-Terán G; Rolland M; Sirivichayakul S; Smith DM; Soares MA; Soriano VV; Ssemwanga D; Stanojevic M; Stefani MA; Sugiura W; Sungkanuparph S; Tanuri A; Tee KK; Truong HM; van de Vijver DA; Vidal N; Yang C; Yang R; Yebra G; Ioannidis JP; Vandamme AM; Shafer RW
    PLoS Med; 2015 Apr; 12(4):e1001810. PubMed ID: 25849352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
    Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
    J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.
    Gupta R; Hill A; Sawyer AW; Pillay D
    Clin Infect Dis; 2008 Sep; 47(5):712-22. PubMed ID: 18662137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
    Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.